The enhancing effect of a laser photochemotherapy with cisplatin or zolendronic acid in primary human osteoblasts and osteosarcoma cells in vitro.
BACKGROUND
Photodynamic therapies (PDT) have become increasingly popular in the adjuvant treatment of different tumour entities. Chemotherapeutic agents, such as cisplatin may be used in combination with low-level laser therapy (LLLT) as laser photochemotherapy. The aim of this study was to investigate the effect of LLLT on cell bioviability of normal and malignant bone cells under chemotherapeutic conditions with either cisplatin or zolendronic acid in vitro.


METHODS
Primary human osteoblasts (HOB) and an osteosarcoma cell line (Saos-2) were treated with different concentrations of zolendronic acid or cisplatin and irradiated twice with a diode laser (wavelength 670 nm, 120 s, energy outputs of 100mW/cm2, continuous wave mode). Cell viability was tested by XTT-assay and via histomorphological analysis.


RESULTS
LLLT alone increased bioviability for both cell lines. LLLT lowered HOB viability at the three highest concentrations of cisplatin and zolendronic acid. For Saos-2, LLLT reduced cell viability at every concentration of cisplatin. In cases of incubation with zolendronic acid, similar to osteoblasts, LLLT lowered cell viability at the highest concentration only.


CONCLUSIONS
Based on the conditions of this study, laser photochemotherapy may be able to raise the cytotoxicity of cisplatin and zolendronic acid in benign and malignant bone cells. This could be of interest in the development of new therapeutic treatment modalities against neoplastic bone diseases like osteosarcoma.
Department of Oral and Maxillofacial Surgery, University of Marburg, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany. heymann.paul@gmail.com.
Paul Günther Baptist
PG
Heymann
Department of Oral and Maxillofacial Surgery, University of Marburg, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
Thomas
T
Ziebart
Department of Oral-Maxillofacial and Plastic Surgery, University of Rostock, Rostock, Germany.
Peer Wolfgang
PW
Kämmerer
Department of Otorhinolaryngology, University of Marburg, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
Robert
R
Mandic
Department of Oral and Maxillofacial Surgery, University of Marburg, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
Akram
A
Saydali
Department of Operative Dentistry and Endodontology, University of Marburg, Marburg, Germany.
Andreas
A
Braun
Department of Oral and Maxillofacial Surgery, University of Marburg, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
Andreas
A
Neff
Department of Oral and Maxillofacial Surgery, University of Marburg, University Hospital Giessen and Marburg, Campus Marburg, Marburg, Germany.
Guy Florian
GF
Draenert
D000970:Antineoplastic Agents / Q000494:pharmacology; D050071:Bone Density Conservation Agents / Q000494:pharmacology; D001859:Bone Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D045744:Cell Line, Tumor; D049109:Cell Proliferation / Q000187:drug effects / Q000528:radiation effects; D048430:Cell Shape / Q000187:drug effects / Q000528:radiation effects; D002470:Cell Survival / Q000187:drug effects / Q000528:radiation effects; D002945:Cisplatin / Q000494:pharmacology*; D004164:Diphosphonates / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D054023:Lasers, Semiconductor / Q000627:therapeutic use; D028022:Low-Level Light Therapy / Q000379:methods*; D010006:Osteoblasts / Q000187:drug effects / Q000473:pathology / Q000528:radiation effects; D012516:Osteosarcoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D000077211:Zoledronic Acid
D000970:Antineoplastic Agents; D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D002945:Cisplatin
bone disease; cisplatin; laser photochemotherapy; zolendronic acid